C12N 2750/00032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2750/00032 (Use of virus as therapeutic agent, other than vaccine) appears on 6 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 10
- Assignees
- 10
- Inventors
- 14
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 3 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by an antisense nucleic acid molecule inhibiting the expression of double homeobox 4 (DUX4)12 May 2026US 12,624,396 B2Fred Hutchinson Cancer Center
- Recombinant virus products and methods for inhibition of expression of DUX431 Oct 2023US 11,802,291 B2Research Institute At Nationwide Children's Hospital
- Engineered viral vector reduces induction of inflammatory and immune responses24 May 2022US 11,339,396 B2President and Fellows of Harvard College
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL15 Dec 2020US 10,865,445 B2Fred Hutchinson Cancer Research Center
- Recombinant virus products and methods for inhibition of expression of DUX428 May 2019US 10,301,649 B2Nationwide Children's Hospital, Inc.
- Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)27 Aug 2026US 2026/0250769 A1Fred Hutchinson Cancer Center
- Recombinant virus products and methods for inhibition of expression of dux426 Sep 2024US 2024/0318201 A1The Research Institute at Nationwide Children' s Hospital
- Engineered viral vector reduces induction of inflammatory and immune responses8 Feb 2024US 2024/0043849 A1President and Fellows of Harvard College
- Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)1 Jul 2021US 2021/0198739 A1Fred Hutchinson Cancer Research Center
- Engineered viral vector reduces induction of inflammatory and immune responses17 Oct 2019US 2019/0316151 A1President and Fellows of Harvard College
Most cited
By later US patents
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL32US 10,865,445 B2Fred Hutchinson Cancer Research Center · 2020
- Recombinant virus products and methods for inhibition of expression of DUX411US 9,469,851 B2Nationwide Children's Hospital, Inc. · 2016
- Recombinant virus products and methods for inhibition of expression of DUX43US 10,301,649 B2Nationwide Children's Hospital, Inc. · 2019
- Engineered viral vector reduces induction of inflammatory and immune responses1US 11,339,396 B2President and Fellows of Harvard College · 2022